Drug intelligence / Profile preview

gentuximab

Development stage: Phase 3
Lead developer: Pfizer
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Gentuximab is an investigational monoclonal antibody being studied for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma. It is administered as an intravenous injection, typically in combination with paclitaxel. The precise molecular target and mechanism of action have not been explicitly detailed in available sources, but as a monoclonal antibody used in oncology, it likely targets a specific protein relevant to tumor growth or survival. Gentuximab is currently being evaluated in clinical trials to assess its efficacy and safety when combined with standard chemotherapy agents such as paclitaxel[10].

Brand names: gentuximab
Other names: gentuximab

Beyond the preview

Go deeper on gentuximab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on gentuximab.

Explore the full profile